1. Home
  2. COTY vs ROIV Comparison

COTY vs ROIV Comparison

Compare COTY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COTY
  • ROIV
  • Stock Information
  • Founded
  • COTY 1904
  • ROIV 2014
  • Country
  • COTY United States
  • ROIV United Kingdom
  • Employees
  • COTY N/A
  • ROIV N/A
  • Industry
  • COTY Package Goods/Cosmetics
  • ROIV Biotechnology: Pharmaceutical Preparations
  • Sector
  • COTY Consumer Discretionary
  • ROIV Health Care
  • Exchange
  • COTY Nasdaq
  • ROIV Nasdaq
  • Market Cap
  • COTY N/A
  • ROIV 8.4B
  • IPO Year
  • COTY 2013
  • ROIV N/A
  • Fundamental
  • Price
  • COTY $7.78
  • ROIV $11.82
  • Analyst Decision
  • COTY Buy
  • ROIV Strong Buy
  • Analyst Count
  • COTY 14
  • ROIV 10
  • Target Price
  • COTY $11.82
  • ROIV $17.39
  • AVG Volume (30 Days)
  • COTY 5.3M
  • ROIV 4.0M
  • Earning Date
  • COTY 11-06-2024
  • ROIV 11-11-2024
  • Dividend Yield
  • COTY N/A
  • ROIV N/A
  • EPS Growth
  • COTY N/A
  • ROIV N/A
  • EPS
  • COTY 0.09
  • ROIV 5.65
  • Revenue
  • COTY $6,118,000,000.00
  • ROIV $158,303,000.00
  • Revenue This Year
  • COTY $7.62
  • ROIV $53.59
  • Revenue Next Year
  • COTY $6.21
  • ROIV $26.91
  • P/E Ratio
  • COTY $88.93
  • ROIV $2.05
  • Revenue Growth
  • COTY 10.15
  • ROIV 101.44
  • 52 Week Low
  • COTY $7.35
  • ROIV $8.29
  • 52 Week High
  • COTY $13.30
  • ROIV $13.06
  • Technical
  • Relative Strength Index (RSI)
  • COTY 35.92
  • ROIV 47.60
  • Support Level
  • COTY $7.52
  • ROIV $11.52
  • Resistance Level
  • COTY $7.71
  • ROIV $12.08
  • Average True Range (ATR)
  • COTY 0.25
  • ROIV 0.22
  • MACD
  • COTY -0.02
  • ROIV -0.01
  • Stochastic Oscillator
  • COTY 23.04
  • ROIV 29.40

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: